Premium
Development of novel blood‐based biomarkers of Alzheimer’s disease
Author(s) -
Dey Sharmistha
Publication year - 2020
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.036230
Subject(s) - neurodegeneration , dementia , disease , alzheimer's disease , medicine , biomarker , tau protein , apolipoprotein e , oncology , bioinformatics , biology , genetics
Background Alzhemier’s disease (AD) is the most common cause of dementia in the elderly. Due to increasing longevity and the lack of a therapy, AD has become not only a major health problem but also imposes substantial social and economic burden worldwide. Alzheimer’s disease are associated with molecular changes that manifest several years before the onset of clinical symptoms. At present, the gold standard for confirmation of neurodegeneration is the neuropathological screening however that is only possible via autopsy of a deceased patient. So, there is a demand for effective diagnostic marker for valid detection. The present studies exploited novel biological molecules having neuropathological role for the development of blood based molecular markers in AD. Method We have determined the level of sirtuins (SIRT), tau, p‐tau, sestrins (SESN) and 5‐LOX proteins for early diagnosis of AD by estimating their serum level in patients through Surface Plasmon Resonance. For developing therapeutics targeting specific proteins, we have used modulator both synthetic and plant product, which specifically modulates the target proteins. Result The serum level of SIRT1, SESN1 & SESN2 were found to be downregulated in AD compare to mild cognitive impairment (MCI) and control elderly group. However, tau, p‐tau and 5‐LOX were found to be significantly upregulated in AD compare to MCI and control. The significant difference in all the proteins level also noticed between control and MCI. ROC result significantly differentiated AD, MCI and control group. The modulator of 5‐LOX, and SIRT1 have been successfully developed. Conclusion Our research will help establish these potential proteins as a plausible candidate for detection and open exciting avenues for therapeutic interventions.